 UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical-stage biotechnology company focused on developing its proprietary GammabodyTM platform of bispecific gamma delta T cell engagers bsTCEs to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the Oppenheimer 32 nd Annual Healthcare Conference 2022. The conference is being conducted in a virtual format and the presentation will take place on Thursday, Mar. 17, 2022 from 8:40 9:10 a.m. ET. 